This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Expression of Nkx3.1 enhances 17β-estradiol anti-tumor
action in PC3 human prostate cancer cells
Ping Wang, Ben Liu, Jin-Dan Luo, Zhi-Gen Zhang, Qi Ma, Zhao-Dian Chen
Department of Urology, The First Affiliated Hospital, Medical College of Zhejiang University, Hangzhou 310003, China
Abstract
Aim: To explore whether the anti-tumor action of
17β-estradiol is enhanced by re-expression of the homeodomain
transcription factor Nkx3.1 in PC3 human
prostate cancer cells. Methods: PC3 cells were stably transfected with
pcDNA3.1-Nkx3.1-His vector, which carries a full-length cDNA of human
Nkx3.1. The PC3 cells stably transfected with vector pcDNA3.1 were set as a control. The expression of Nkx3.1 protein in the cells was confirmed by
Western blot analysis. The effect of
Nkx3.1 on cell proliferation of PC3 cells was examined with MTT assay. The
antiproliferative and apoptotic effects of 17β-estradiol alone or
in combination with Nkx3.1 were estimated on PC3
cells by using MTT growth tests and flow cytometric analyses. The expression of apoptosis-related proteins was
analyzed using Western blotting. Results:
The plasmid carrying Nkx3.1 gene induced high expression of Nkx3.1
protein in PC3 cells. The re-expression of exogenous Nkx3.1 did not cause a significant reduction in cellular proliferation,
whereas the expression of Nkx3.1 enhanced the
17β-estradiol anti-proliferative effect in PC3
cells. Nkx3.1 expression promoted 17β-estradiol-induced apoptosis of PC3 cells, as shown by
analysis of Bcl-2, Bax, Caspase-3 and poly (ADP-ribose) polymerase
expression. Conclusion: The present study demonstrates that
re-expression of Nkx3.1 enhances 17β-estradiol anti-tumor action in PC3 human prostate cancer cells.
The in vitro study suggests that re-expression of
Nkx3.1 is worthy of further consideration as an adjuvant treatment of androgen independent prostate
cancer with estrogen anti-tumor therapies. (Asian J Androl 2007 May; 9: 353_360)
Keywords: apoptosis; estrogen;
Nkx3.1; prostate cancer cell; 17β-estradiol; androgen independent prostate cancer
Correspondence to: Prof. Zhao-Dian Chen or Dr Ben Liu, Department of Urology, The First Affiliated Hospital, Medical College of
Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, China.
Tel: +86-571-8723-6833 Fax: +86-571-8723-6594
E-mail: zdchenzju@126.com or drliuben@sina.com.cn
Received 2006-06-03 Accepted 2007-03-10
DOI: 10.1111/j.1745-7262.2007.00278.x
1 Introduction
Initial treatment for patients with advanced or recurrent prostate cancer is typically surgical or medical castration:
androgen deprivation therapy (ADT). Although most cases initially respond to androgen deprivation, eventually this
therapy fails and the patient dies of recurrent androgen-independent prostate cancer (AIPC). The lack of effective
therapies for AIPC continues to spur new efforts to find therapeutic avenues for managing this prevalent male neoplasm.
Estrogen therapies, such as diethylstilbesterol (DES), PC-SPES, transdermal estradiol and conjugated estrogens,
are effective in the treatment of AIPC [1, 2]. Oral estrogen treatment with DES, once the most common method for
hormone manipulation of prostate cancer, was largely abandoned in the 1970s because of its significant
thromboembolic and cardiovascular toxicity [3]. However, in the mid-1980s, interest in estrogen therapy was renewed when it
was found that estrogen given parenterally did not induce such side effects [3, 4]. A phase II study of transdermal
estradiol in patients with AIPC demonstrated that
estradiol was well tolerated and produced a modest response
rate, but was not associated with thromboembolic
complications or clinically important changes in several
coagulation factors [2].
Nkx3.1 is a prostate-specific homeobox gene that is
located on chromosome 8p21 [5]. Null alleles of
Nkx3.1 in mice results in impaired prostate development as well
as hyperplasia and dysplasia of the prostate. In addition,
the Nkx3.1 gene maps to a region of high loss of
heterozygosity in prostate cancer in humans, suggesting that
Nkx3.1 might have a direct role in prostate carcinogenesis,
possibly functioning as a tumor suppressor protein [6,
7]. Loss of Nkx3.1 expression is strongly associated
with hormone-refractory disease and advanced tumor
stage in prostate cancer [8]. In the LNCaP
androgen-dependent prostate cancer cell line,
Nkx3.1 is expressed at a basal level that increases upon androgen stimulation.
In contrast, there is no Nkx3.1 expression in
androgen-independent PC3 cells [9]. In addition to androgens,
Nkx3.1 expression is upregulated by 17β-estradiol [10].
Based on the results of the abovementioned studies, we
hypothesized that the re-expression of
Nkx3.1 would enhance estradiol anti-tumor action in PC3 human prostate
cancer cells.
The objective of the present study is to investigate
whether the anti-tumor action induced by estradiol could
be enhanced by the restoration of Nkx3.1 expression in
PC3 cells.
2 Materials and methods
2.1 Cell culture
PC3 and LNCaP, derived from human prostate cancer, were obtained from the American Type Culture
Collection (Rockville, MD, USA). The cells were
maintained in RPMI-1640 medium (Hyclone, Utah, USA) with
10% fetal bovine serum at 37°C in a humidified
atmosphere with 5% CO2.
2.2 Expression and reporter plasmid construction
Total RNA was isolated from normal prostate tissue
using TRIzol (Invitrogen, California, USA) according to
the manufacturer's instructions. Two micrograms of
total RNA was used for cDNA synthesis (SuperScript
III Reverse Transcriptase; Invitrogen, California,
USA) and one-tenth of the obtained cDNA was used to amplify
Nkx3.1 and Nkx3.1-HisTag by polymerase chain reaction
(PCR). The conditions of PCR for each individual gene
were optimized to analyze amplified product in the linear
range of amplification by adjusting amplification cycles
for each set of primer. The nucleotide sequences of the
primers used to amplify the Nkx3.1 and
Nkx3.1-HisTag genes were as follows:
Nkx3.1, sense primer 5'-CGC GGA TCC GCG ATG CTC AGG GTT CCG GAG C-3'
and antisense primer 5'-CCG GAA TTC CGG TTA CCC AAA AGC TGG GCT C-3',
Nkx3.1-HisTag, sense primer 5'-CGC GGA TCC GCG ATG CTC AGG GTT CCG GAG
C-3' and antisense primer 5'-CCG GAA TTC TTA ATG GTG ATG ATG CCC AAA AGC TGG GCT CCA GC-3'.
The amplified Nkx3.1 and
Nkx3.1-His DNA samples were cloned into a pGEM-T Easy vector (Promega,
Wisconsin, USA), following the protocol provided by the
manufacturer. The DNA were digested with
EcoRI and BamHI restriction enzymes and the fragment representing
Nkx3.1 and Nkx3.1-His cDNA were excised from a 1%
agarose gel. The DNA was purified using a QIAquick
Gel extraction Kit (Qiagen, Hilden, Germany). The
resulting Nkx3.1-His fragment was directionally cloned into the
EcoRI and BamHI restriction sites of plasmid
pcDNA3.1(_) (Invitrogen, California, USA).
Nkx3.1 was cloned into pEGFP-C1 (Clontech, California,
USA) at BglII and EcoRI sites. The successful cloning was confirmed by
sequencing the plasmid.
2.3 Stable transfection of PC3 cells
For transfection, plasmid DNA were prepared using
a Qiagen plasmid midi kit (Qiagen GmbH, Hilden, Germany). PC3 cells were seeded at a concentration of
5 × 105 cells per well into 6 well culture dishes. Cells
were allowed to adhere overnight, and the next day
washed twice with serum-free RPMI-1640. Transfection solution containing Lipofectamine 2000 (Invitrogen,
California, USA) and DNA (pcDNA3.1,
pcDNA3.1-Nkx3.1-His, GFP-Nkx3.1) was carefully overlaid and incubated
with the cells for 5 h. RPMI-1640 with 10% fetal
bovine serum was next added and the cells were incubated
for 2 days, with media being replaced every day. On the
third day, medium was replaced with selection medium
containing 500 μg/mL of G418. Stable clones were
isolated using cloning cylinders and grown continuously
under G418 selection pressure.
2.4 Proliferation assay
To analyze the effect of Nkx3.1 on cell growth, MTT
assay (CellTiter 96 nonradioactive cell proliferation
assay kit [Promega]) was used to quantify cell proliferation.
Nkx3.1-PC3 and pcDNA3.1-PC3 cells were plated in 96
well plates at a density of
5.0 × 103 cells per well
containing 100 μL of culture medium. After 0, 24, 48, 72,
96 and 120 h culture, MTT (0.5 mg/mL in
phosphate-buffered saline [PBS]) was added to each well and
incubated for 4 h at 37°C. The medium was then carefully
aspirated, and dimethyl sulfoxide was added to solubilize
the colored formazan product. Absorbance value was
read on a scanning multiwell spectrophotometer
(Bio-Rad, California, USA) with 570 nm wavelength after
agitating the plates for 5 min on a shaker. Each
experimental condition was performed in six preparations and
repeated three times.
Following stable transfection of PC3 cells, the cells
were treated with various concentrations of
17β-estradiol (Sigma). Nkx3.1-PC3 and pcDNA3.1-PC3 cells were
weaned off steroids in phenol red-free RPMI-1640
supplemented with 10% charcoal dextran-treated fetal calf
serum before experiments. Cells were estrogen-depleted
for 3 days and then plated in 96 well plates at a density
of 5.0 × 103 cells per well and treated with various
concentrations of 17β-estradiol. Proliferation assay was
performed as described above.
2.5 Flow cytometric analysis of cell apoptosis
Annexin V (Annexin V-FITC) and propidium iodide
(PI) double staining was used to determine apoptosis.
Annexin V binds to cells that express phosphatidylserine
on the outer layer of the cell membrane, and PI stains
cellular DNA of cells with a compromised cell membrane.
Cells that stain positive for Annexin V-FITC and negative
for PI are undergoing apoptosis. Cells that stain positive
for both Annexin V-FITC and PI are either in the end
stage of apoptosis, or are already dead. Cells that stain
negative for both Annexin V-FITC and PI are alive and
not undergoing measurable apoptosis. Cells were
collected and washed twice with cold PBS and were
resuspended in 1× binding buffer at a concentration of
1 × 106 cells/mL. Cells were double stained with
FITC-conjugated annexin V and PI for 15 min at room temperature.
Annexin V and PI were added according to the manufacturer's recommendations (BD, pharMingen, San
Diego, CA, USA). Samples were immediately analyzed
by flow cytometry.
2.6 Western blot analysis
Treated cells were washed with cold PBS and lysed in
protein extraction buffer (20 mmol/L Tris, pH 8.0,
137 mmol/L NaCl, 10% glycerol, 1% Nonidet P-40, 0.1%
SDS, 0.5% sodium dexycholate, 2 mmol/L EDTA) containing protease inhibitors (Cocktail set III, Calbiochem,
California, USA). The protein concentration of each
sample of the tumor cell lysates was quantified using
Coomassie protein assay reagent (Pierce, Rockford, IL,
USA). An equal amount of protein was subjected to 10%
SDS-PAGE and transferred to polyvinylidene difluoride
membrane by blotting overnight at 30V/35 mA.
Membranes were blocked for 2 h at room temperature in 5%
(w/v) non-fat milk/Tris-buffered saline with 0.1% (v/v)
Tween-20. Western blotting was carried out overnight
at 4°C using the following antibodies: Nkx3.1 polyclonal
antibody (1:200; H-50, Santa Cruz Biotechnology).
His-Tag monoclonal antibody (1:1000; 70796-4, Novagen,
Darmstadt, USA), Bax monoclonal antibody (1:200;
B-9, Santa Cruz Biotechnology, California, USA), Bcl-2
monoclonal antibody (1:200; C-2, Santa Cruz Biotechnology, California, USA), Caspase-3 monoclonal
antibody (1:200; E-8, Santa Cruz Biotechnology, California, USA), poly(ADP-ribose) polymerase (PARP)
monoclonal antibody (1:200; F-2, Santa Cruz Biotechnology, California, USA) and
glyceraldehydes-3-phosphate dehydrogease monoclonal antibody (1:5 000;
Acris antibodies GmbH, Hiddenhausen, Germany). Blots
were then incubated with 1:2 000 dilution for goat
anti-rabbit IgG peroxidase conjugated secondary antibody
(Sunnyvale, CA, USA) or 1:2 000 diluation for goat
anti-mouse IgG peroxidase conjugated secondary antibody
(Santa Cruz Biotechnology, California, USA), washed,
and developed by enhanced chemiluminescence (Pierce,
Rockford, IL, USA).
2.7 Statistical analysis
For all groups, data are presented as the mean ± SE.
Results were analyzed by one-way analysis of variance
and Student's t-test to identify significant differences
between groups. The levels of statistical significance
were set at P < 0.05, and all statistical calculations were
done using SPSS software (version 10.1, SPSS, Chicago,
IL, USA).
3 Results
3.1 Nkx3.1 expression in stably transfected PC3 cells
Following stable transfection of PC3 cells, reporter
gene expression was analyzed by fluorescence microscopy.
Many brightly fluorescence cells were found in stably
transfected Nkx3.1-GFP-PC3 cells (Figure 1A).
To confirm Nkx3.1-His expression in stably
transfected PC3 cells, Western blotting was performed using
the lysates. Figure 1B shows the results for
anti-Nkx3.1 and anti-His. There was a basal level of Nkx3.1 in LNCaP
cells (38 kDa). No detectable Nkx3.1 protein was seen
in pcDNA3.1-PC3 cells or PC3 cells, whereas
Nkx3.1-His delivery enabled a high expression of Nkx3.1 fusion
protein (approximately 39 kDa). To further assess the
Nkx3.1 fusion protein, Western blotting was performed
using anti-His. The results indicate that the expression
of His was in accordance with Nkx3.1.
3.2 Nkx3.1 enhances 17β-estradiol antiproliferative
effect in PC3 cells
To assess the potential role of Nkx3.1 in human
prostate cancer PC3 cell growth, PC3 cells were stably
transfected with Nkx3.1-pcDNA3.1 or pcDNA3.1. Figure 2A
shows the effect of Nkx3.1 on the proliferation of PC3
cells. Proliferation status was assessed by MTT assay.
Our results demonstrate that stably transfected PC3 cells
fail to produce a measurable difference between
Nkx3.1-PC3 group and pcDNA3.1-PC3 group at any of the time
point.
Next, we addressed the question of whether exogenous
Nkx3.1 expression could enhance the antiproliferative
effect of 17b-estradiol in PC3 cells. Figure 2B shows the
effect of 17β-estradiol on the growth of Nkx3.1-PC3 and
pcDNA3.1-PC3 cells after 5 days of exposure.
Nkx3.1-PC3 cells and pcDNA3.1-PC3 cells displayed a
significant, dose-related inhibition of growth, with a maximal effect at
100 nmol/L of 17β- estradiol. Nkx3.1-PC3 cells produced
a significantly lower absorbance at the 120 h time-point
compared with the pcDNA3.1-PC3 cells at concentrations higher than 0.1 nmol/L
17β-estradiol (0.1 nmol/L, P < 0.05; 1 nmol/L,
P < 0.05; 10 nmol/L, P < 0.01;
100 nmol/L, P < 0.001). The results revealed that stable
expression of Nkx3.1 in PC3 cells could enhance the
antiproliferative effect of 17β-estradiol.
3.3 Nkx3.1 expression-promoted 17β-estradiol-induced
apoptosis of PC3 cells
The significant inhibition of proliferative activity in
PC3 human prostate cancer cells by 17β-estradiol has
been proven. To clarify whether Nkx3.1
expression-promoted 17β-estradiol -inhibited cell growth was a result
of the induction of apoptosis, an alternative evaluation of
apoptosis was completed by means of Annexin V-FITC
analysis. With this assay, apoptotic and necrotic
subpopulations could be distinguished. The apoptotic rates
of Nkx3.1-PC3 and pcDNA3.1-PC3 cells were quantified by Annexin V and PI double staining followed by
cytometry analysis after 5 days of 17β-estradiol
exposure (Figure 3A and B). The loss of plasma membrane
asymmetry is an early event in apoptosis and could
result in the exposure of phosphatidylserine residues at the
outer plasma membrane leaflet. Annexin V, a
phospholipid binding protein, specifically binds to
phosphati-dylserine residues. The Annexin V-FITC binding assay
showed that pcDNA3.1-PC3 cells displayed a slight,
dose-related increase of apoptosis, whereas a striking
increase in apoptotic cells was observed in the
Nkx3.1-PC3 group (Figure 3C). The results show that Nkx3.1
expression promoted 17β-estradiol-induced apoptosis of
PC3 cells. However, these results also indicate that
expression of Nkx3.1 enhances the 17β-estradiol
antiproliferative effect, at least in part as a result of the higher
proportion of apoptotic cells in the Nkx3.1-PC3 group.
3.4 Expression of apoptosis-related protein in
Nkx3.1-PC3 and pcDNA3.1-PC3 cells treated with
17β-estradiol
The effect of different treatments on expression of
the Bcl-2 family of anti-apoptotic and pro-apoptotic
proteins was determined to gain insights into the
mechanism for apoptosis. The protein expression levels of
Bcl-2 and Bax in Nkx3.1-PC3 and pcDNA3.1-PC3 cells
treated with 0.1 nmol/L, 1 nnmol/L,10 nnmol/L or
100 nnmol/L of 17β-estradiol for 5 days was analyzed by
Western blot analysis. As shown in Figure 4, there was
striking downregulation of the level of Bcl-2 expression in
Nkx3.1-PC3 cells treated with 1 nnmol/L, 10 nnmol/L or
100 nnmol/L of 17β-estradiol. In contrast, the
expression level of Bax was upregulated. These observations
indicate that Nkx3.1 expression-promoted
17β-estradiol-induced apoptosis might be manifested by an increase in
the ratio of Bax to Bcl-2.
The effect of 17β-estradiol on Nkx3.1-PC3 cellular
apoptosis corresponded to a decrease in caspase-3
protein expression (caspase-3 activation is presented by the
loss of its pro-form). Caspase-3 is one of the
executioner caspases in response to the activation of the
intrinsic mitochondrial apoptotic pathway, which can be
triggered by a blockade of ErbB signaling [11, 12]. When
caspase-3 is actived, the intact form of the 33 kDa is
cleaved into an activated form of 17/19 kDa, which in
turn cleaves PARP [12]. Consistent with the caspase-3
activation results, 17β-estradiol markedly increased the
level of cleaved PARP in Nkx3.1-PC3 cells. The results
suggest that increased apoptosis induced by the
17β-estradiol in Nkx3.1-PC3 cells is triggered by activation
of caspase-3 and regulated by Bcl-2 family proteins.
4 Discussion
Prostate cancer is one of the most common human
malignancies: thus far, there has been no effective therapy
for the treatment of AIPC. In the present study, we
developed an in vitro system; namely, PC3 cell lines that
were stably transfected with Nkx3.1 cDNA. Although
Nkx3.1 failed to produce significant growth inhibition,
we found that exogenous expression of Nkx3.1 protein
in human prostate cancer PC3 cells promoted the antiproliferative effect of
17β-estradiol, which was associated with cellular apoptosis. The fact that
Nkx3.1 expression-promoted 17β-estradiol-induced apoptosis
might be a result of an increase in ratio of Bax to Bcl-2
further indicates that caspase-3 is activated, which in
turn cleaves PARP. These results suggest that the
combining use of Nkx3.1 and 17β-estradiol possesses novel
anti-tumor action on PC3 human prostate cancer cells.
There are some divergent viewpoints about whether
Nkx3.1 is a true tumor suppressor gene. Bhatia-Gaur
et al. [13] consider Nkx3.1 to be a prostate-specific tumor
suppressor gene and posit that loss of a single allele might
predispose to prostate carcinogenesis. Kim
et al. [14] found that overexpression of
Nkx3.1 resulted in an approximate 70% reduction in cellular proliferation in
rodent AT6 cells and a 60% reduction in PC3 cells. Lei
et al. [15] demonstrate that
Nkx3.1 inhibits AKT phosphorylation/activation through an AR-dependent
mechanism and show that Nkx3.1 expression in
vivo can block the hyperproliferative and antiapoptotic effects brought
on by phosphatase and tensin homolog (PTEN, mutated
in multiple advanced cancers 1) loss. In contrast, some
scholars suggest that Nkx3.1 does not function as a
typical tumor suppressor protein in prostate cancer, such as
P53, retinoblastoma or PTEN [8, 9, 16]. Instead,
Nkx3.1 appears to act more like a tumor modulator, serving as a
regulator of differentiation, which in turn prevents
cancer initiation. In the present study, we found that
overexpression of exogenous Nkx3.1 did not display a
significant reduction in cellular proliferation. Our results
provide support for the idea that Nkx3.1 does not function as a
typical tumor suppressor gene: by restoring
Nkx3.1 expression it is not sufficient for inhibiting growth of PC3 cells.
Interest in estrogen therapy has also been rekindled
by recent trials suggesting that parenteral administration
of estrogens might result in the avoidance of much
cardiovascular toxicity [4]. Most recently, Ockrim
et al. [17] reported encouraging biochemical results in 20
patients with locally advanced or metastatic cancer treated
with transdermal estradiol patches. Nevertheless,
estrogens produced biochemical responses only in
one-quarter to two-thirds of patients in whom primary androgen
deprivation therapy failed [1, 18]. Therefore, enhancing
estrogen anti-tumor action might have the most
significant clinical impact. We found that 17β-estradiol is an
effective inhibitor of human prostate cancer PC3 cells.
Our result is in agreement with a report by Carruba
et al. [19], which also stated that
17β-estradiol is an effective inhibitor of PC3 cells and displays a significant,
dose-related inhibition of growth. In our study, to investigate
the effects of the combination of Nkx3.1 transfection and
17β-estradiol on PC3 cells growth in vitro, Nkx3.1-PC3
cells and pcDNA3.1-PC3 cells were incubated with increasing
concentrations of 17β-estradiol, from 0.01 nmol/L up to
100 nmol/L. Our results demonstrate that plasmid
stably transfected from Nkx3.1 into PC3 cells that do not
express this gene, resulted in a significantly higher
antiproliferative effect of 17β-estradiol (0.1 nmol/L or
more) against PC3 cells compared to the control group.
Consistent with our proliferation assay, stable
expression of Nkx3.1 promotes 17β-estradiol-induced apoptosis.
These results suggest that the effect of the
Nkx3.1-enhanced 17β-estradiol antiproliferative effect is a result of
the Nkx3.1-amplified 17β-estradiol-induced apoptosis.
In our study, we also tried to elucidate some
molecular mechanisms by which Nkx3.1
expression-promoted 17β-estradiol-induced apoptosis of PC3 cells.
Several pathways are known to lead to apoptosis. The
Bcl-2 family and caspase-3 are important regulators of
apoptosis. Several studies demonstrate that the increased
expression of Bcl-2 in prostate cancer confers androgen
resistance, particularly in advanced disease, and might
facilitate progression to androgen independence [20, 21].
Bcl-2 is part of an expanding family of
apoptosis-regulatory molecules, which might act as either death
antagonists (Bcl-2, Bcl-xl and Mcl-1) or death agonists (Bax,
Bak, Bcl-xS, Bad and Bid). The selective and
competitive dimerization between pairs of antagonists and
agonists determines how a cell will respond to a given signal.
It has been reported that Bax inactivates Bcl-2 proteins,
which protect cells from apoptosis and that the ratio of
Bax/Bcl-2 increases during apoptosis [22, 23]. The Bax
protein levels were increased in the 17β-estradiol-treated
Nkx3.1-PC3 cells, leading to an increase in the ratio of
Bax to Bcl-2, which might be responsible for inducing
apoptotic processes in our system. However, the
precise molecular actions on the members of the Bcl-2
family require further investigation. Nevertheless, it is clear
that Nkx3.1 expression-promoted apoptosis by
17β-estradiol on PC3 cells is at least in part a result of
inactivation of Bcl-2 and a great elevation of Bax expression.
In normal prostate cells, PTEN inhibits the
phosphatidy-linositol 3-kinase (PI3K) pathway. Activation of this
pathway stimulates Akt, which inactivates several proapoptotic
proteins, therefore enhancing cell survival. During
androgen-independent progression, the loss of PTEN
reverses the inhibition of the PI3K-Akt pathway,
permitting activated Akt to phosphorylate Bad. This activation
results in the release of Bcl-2, which eventually leads to
cell survival [24]. It is of value to further address whether
the PI3K-Akt signal pathway has been connected with
the alteration of Bcl-2 and Bax proteins expression
during Nkx3.1 expression-promoted 17β-estradiol-induced
apoptosis.
Caspase activation leads to cleavage and inactivation
of key cellular proteins, such as poly (ADP-ribose )
polymerase [25]. We found that the activation of caspase-3
was enhanced by 17β-estradiol in Nkx3.1-PC3 cells.
Consistent with the caspase-3 activation results,
17β-estradiol markedly increased the level of cleaved PARP
in Nkx3.1-PC3 cells. Caspase-3 is an executioner caspase
that can be activated by a mitochondrial pathway
involving caspase-9 or a death receptor pathway involving
caspase-8 [25]. Of particular interest in our finding is
that Nkx3.1 expression-promoted 17β-estradiol-induced
apoptosis appears to involve the mitochondrial pathways,
as demonstrated by the increase in Bax protein
expression and the cleaved PARP.
In summary, this report describes a potentially
useful approach in the treatement of AIPC: the expression
of Nkx3.1 enhances 17β-estradiol anti-proliferative
effects on PC3 cells. In particular, expression of
Nkx3.1 promotes 17β-estradiol multiple anti-tumor effects of
activation of caspase-3 and PARP, downregulation of
Bcl-2 protein and upregulation of Bax protein expression,
triggering cellular apoptosis. Our in
vitro study suggests that the re-expression of
Nkx3.1 is worthy of further consideration as an adjuvant method in the
treatment of AIPC with estrogen anti-tumor therapy.
Acknowledgment
We would thank Prof. Rong-Zhen Xu for the expert
technical assistance in the study.
References
1 Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M,
Pienta KJ. A phase II trial of oral diethylstilbesterol as a
second-line hormonal agent in advanced prostate cancer. Urology
1998; 52: 257_60.
2 Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff
KG, Beer TM, et al. Phase II study of transdermal estradiol in
androgen-independent prostate carcinoma. Cancer 2005; 103:
717_23.
3 Tammela T. Endocrine treatment of prostate cancer. J Steroid
Biochem Mol Biol 2004; 92: 287_95.
4 Hedlund PO, Henriksson P. Parenteral estrogen versus total
androgen ablation in the treatment of advanced prostate carcinoma:
effects on overall survival and cardiovascular mortality. The
Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
Urology 2000; 55: 328.
5 Bieberich CJ, Fujita K, He WW, Jay G. Prostate-specific and
androgen-dependent expression of a novel homeobox gene. J
Biol Chem 1996; 271: 31779_82.
6 Shen MM, Abate-Shen C. Roles of the
Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Dev Dyn
2003; 228: 767_78.
7 Jiang AL, Zhang PJ, Chen WW, Liu WW, Yu CX, Zhang
JY, et al. Effect of 9-cis retinoic acid on human homeobox gene
Nkx3.1 expression in prostate cancer cell line LNCaP. Asian J
Andol 2006; 8: 435_41.
8 Bowen C, Bubendorf L, Voeller HJ, Slack R, Willi N,
Kallioniemi OP, et al. Loss of
Nkx3.1 expression in human prostate cancers correlates with tumor progression. Cancer
Res 2000; 60: 6111_5.
9 Korkmaz CG, Korkmaz KS, Manola J, Xi Z, Risberg B,
Saatcioglu F, et al. Analysis of androgen regulated homeobox
gene Nkx3.1 during prostate carcinogenesis. J Urol 2004; 172:
1134_39.
10 Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S,
Pretlow TG, Saatcioglu F. Full-length cDNA sequence and
genomic organization of human NKX3A_alterative forms and
regulation by both androgens and estrogens. Gene 2000; 260:
25_36.
11 Grant S, Qiao L, Dent P. Roles of ERBB family receptor
tyrosine kinases, and downstream signaling pathway, in the
control of cell growth and survival. Front Biosci 2002; 7:
d376_89.
12 Patel T, Gores GJ, Kaufmann SH. The role of proteases
during apoptosis. FASEB J 1996; 10: 587_97.
13 Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, Kim M, Desai
N, Shen MM, et al. Roles for Nkx3.1 in prostate development
and cancer. Genes Dev 1999; 13: 966_77.
14 Kim MJ, Bhatia-Gaur R, Banach-Petrosky WA, Desai N, Shen
MM, Abate-Shen C, et al. Nkx3.1 mutant mice recapitulate
early stages of prostate carcinogenesis. Cancer Res 2002; 62:
2999_3004.
15 Lei Q, Jiao J, Xin L, Chang CJ, Wang S, Wu H,
et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate
cancer initiation caused by PTEN loss. Cancer Cell 2006; 9:
367_78.
16 Swalwell JI, Vocke CD, Yang Y, Walker JR, Grouse L,
Emmert-Buck MR, et al. Determination of a minimal deletion interval
on chromosome band 8p21 in sporatic prostate cancer. Genes
Chromosomes Cancer 2002; 33: 201_5.
17 Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD.
Transdermal estrogen therapy for advanced prostate
cancer-forward to the past? J Urol 2003; 169: 1735_7.
18 Carroll PR, Altwein J, Brawley O, Cockett A, Cooperberg M,
Hirao Y, et al. Management of disseminated prostate cancer.
In: Denis L, Bartsch G, Khoury S, Murai M, Partin A, editors.
The 3rd International Consultation on Prostate Cancer. June
21_23, 2002, Paris, France. UK: Plymbridge Distributors;
2003; 251_84.
19 Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E,
Castagnetta L, et al. Estradiol inhibits growth of
hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res
1994; 54: 1190_3.
20 McConkey DJ, Greene G, Pettaway CA. Apoptosis resistance
increases with metastatic potential in cells of the human LNCaP
prostate carcinoma line. Cancer Res 1996; 56: 5594_99.
21 Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS,
Buttyan R, et al. Overexpression of Bcl-2 protects prostate
cancer cells from apoptosis in vitro and confers resistance to
androgen depletion in vivo. Cancer Res 1995; 55: 4438_45.
22 Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes
in vivo with a conserved homolog, Bax, that accelerates
programmed cell death. Cell 1993; 74: 609_19.
23 Sedlak TW, Oltvai ZN, Yang E, Wang K, Boise LH,
Thompson CB, et al. Multiple Bcl-2 family members demonstrare
selective dimerizations with Bax. Pro Natl Acad Sci USA 1995;
92: 7834_38.
24 Debes JD, Tindall DJ. Mechanisms of Androgen-Refractory
Prostate Cancer. N Engl J Med 2004; 351: 1488_90.
25 Wolf BB, Green DR. Suicidal tendencies: apoptotic cell death by
caspase family proteinases. J Biol Chem 1999; 274: 20049_52. |